Literature DB >> 25680810

The anti-canine distemper virus activities of ex vivo-expanded canine natural killer cells.

Ji-Yun Park1, Dong-Jun Shin2, Soo-Hyeon Lee2, Je-Jung Lee3, Guk-Hyun Suh4, Duck Cho5, Sang-Ki Kim6.   

Abstract

Natural killer (NK) cells play critical roles in induction of antiviral effects against various viruses of humans and animals. However, few data on NK cell activities during canine distemper virus (CDV) infections are available. Recently, we established a culture system allowing activation and expansion of canine non-B, non-T, large granular NK lymphocytes from PBMCs of normal dogs. In the present study, we explored the ability of such expanded NK cells to inhibit CDV infection in vitro. Cultured CD3-CD5-CD21- NK cells produced large amounts of IFN-γ, exhibited highly upregulated expression of mRNAs encoding NK-cell-associated receptors, and demonstrated strong natural killing activity against canine tumor cells. Although the expanded NK cells were dose-dependently cytotoxic to both normal and CDV-infected Vero cells, CDV infection rendered Vero cells more susceptible to NK cells. Pretreatment with anti-CDV serum from hyperimmunized dogs enhanced the antibody-dependent cellular cytotoxicity (ADCC) of NK cells against CDV-infected Vero cells. The culture supernatants of NK cells, added before or after infection, dose-dependently inhibited both CDV replication and development of CDV-induced cytopathic effects (CPEs) in Vero cells. Anti-IFN-γ antibody neutralized the inhibitory effects of NK cell culture supernatants on CDV replication and CPE induction in Vero cells. Such results emphasize the potential significance of NK cells in controlling CDV infection, and indicate that NK cells may play roles both during CDV infection and in combating such infections, under certain conditions.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral effects; Canine; Canine distemper virus; IFN-γ; NK cells

Mesh:

Substances:

Year:  2015        PMID: 25680810     DOI: 10.1016/j.vetmic.2015.01.021

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

Review 1.  Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Comp Oncol       Date:  2020-05-26       Impact factor: 2.385

2.  Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.

Authors:  Yoseop Kim; Soo-Hyeon Lee; Cheol-Jung Kim; Je-Jung Lee; Dohyeon Yu; Soomin Ahn; Dong-Jun Shin; Sang-Ki Kim
Journal:  BMC Vet Res       Date:  2019-10-14       Impact factor: 2.741

3.  Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.

Authors:  Robert Hullsiek; Yunfang Li; Kristin M Snyder; Sam Wang; Da Di; Antonella Borgatti; Chae Lee; Peter F Moore; Cong Zhu; Chiara Fattori; Jaime F Modiano; Jianming Wu; Bruce Walcheck
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

4.  NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells.

Authors:  Jennifer A Foltz; Srinivas S Somanchi; Yanwen Yang; Arianexys Aquino-Lopez; Erin E Bishop; Dean A Lee
Journal:  Front Immunol       Date:  2016-11-23       Impact factor: 7.561

5.  Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3+CD5dimCD21- Cytotoxic Large Granular Lymphocytes.

Authors:  Soo-Hyeon Lee; Dong-Jun Shin; Yoseop Kim; Cheol-Jung Kim; Je-Jung Lee; Mee Sun Yoon; Tung Nguyen Thanh Uong; Dohyeon Yu; Ji-Youn Jung; Duck Cho; Bock-Gie Jung; Sang-Ki Kim; Guk-Hyun Suh
Journal:  Front Immunol       Date:  2018-04-27       Impact factor: 7.561

Review 6.  Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy.

Authors:  Alicia A Gingrich; Jaime F Modiano; Robert J Canter
Journal:  J Clin Med       Date:  2019-10-27       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.